Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets

<table class="table-group" id="tab11"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Responses</td><td class="align_center">Predicted value</td><td class="align_center">Experimental value</td><td class="align_center">% error</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">Friability (%)</td><td class="align_center">0.302</td><td class="align_center">0.294 ± 0.010</td><td class="align_center">2.72</td></tr><tr><td class="align_left">Disintegration time (sec)</td><td class="align_center">18.7</td><td class="align_center">19.20 ± 0.84</td><td class="align_center">3.64</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>Evaluation of the optimized FDC of MET HCl and GLB ODTs.<br/></div></td></tr></table>

<div>Predicted and experimental response values and percentage error obtained at optimal levels of the factors.</div>

Advances in Pharmacological and Pharmaceutical Sciences

tab11

Table 11

Table 11: Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets 